[Correspondence] Fuzuloparib plus apatinib in BRCA-mutated breast cancer: balancing efficacy and accessibility in regional China – Authors' reply

The Lancet Oncology | |

We thank Ziran Qiu and Na Jin for their Correspondence regarding the FABULOUS trial1 and appreciate their practical perspectives.

Topics: breast-cancer, cervical-cancer